Veterinary Vaccine Adjuvants Market to Reach $530.4 Million by 2027; Attributed to Rising Focus on Long Lasting Vaccines for Zoonotic Diseases

The global veterinary vaccines market size is projected to reach USD 530.4 million by 2027 owing to the rising prevalence of infectious diseases among animals. Veterinary vaccines adjuvants are chemicals or microbial components used in a vaccine for enhancing its healing power and increase immunity in animals.  A recently published report by Fortune Business Insights™ titled, “Veterinary Vaccine Adjuvants Market Size, Share & Industry Analysis, By Type (Alum and Calcium Salts, Oil Emulsion Adjuvants, Liposomes, and Archaeosomes, Nanoparticles and Microparticles, and Others), By Application (Research, and Commercial), By Route of Administration (Oral, Subcutaneous, Intramuscular, and Others), By Animal Type (Livestock Animal, and Companion Animal) and Regional Forecast, 2020-2027”, offers an in-depth overview of the market and its growth parameters. According to this report, the market value was USD 380.0 million in 2019 and will exhibit a CAGR of 4.3 % between 2019 to 2026.

Collaborative Efforts to Support Growth Initiatives will Bode Well for Phibro Animal Health Corporation

In January 2016, Phibro Animal Health Corporation acquired MVP Laboratories Inc. After the acquisition, Phibro has been able to focus more on its animal vaccine business.  Jack Bendheim, the Chairman, President, and the Chief Executive Officer of Phibro said, “This partnership will help us build excellent strategies for supporting our growth initiatives and broaden our portfolio of phibro vaccines. These vaccines are offering a growth platform and creating value for our future vision, i.e.  strong product development. Our main objective is to expand our products across North America and gather more revenue for the future market.” Such initiatives are likely to add impetus to the market in the coming years.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/veterinary-vaccine-adjuvants-market-101155

Government-supported Awareness Programs will Augment Growth

Increasing awareness about animal health and welfare is the key factor boosting the veterinary vaccines adjuvants market growth. In addition to this, government-supported initiatives to promote the advantages of animal farming, animal husbandry, and animal vaccination will also aid in the expansion of the market in the coming years. Moreover, the increasing incidences of infectious zoonotic diseases will also promote growth.  The Centers for Disease Control and Prevention (CDC) states an estimate of six out of every 10 known infectious diseases in humans is spread from animals and three out of every four new diseases discovered in humans are spread from animals. This, zoonotic diseases and the need for vaccination are major growth factors adding impetus to the overall market.

On the contrary, vaccine adjuvants for animals may have adverse effects such as uveitis, anorexia, fever, lethargy, and soreness. This may hamper the overall market size in the coming years. Nevertheless, increasing investments in research and development of animal vaccines and increasing pet healthcare insurance policies will create lucrative growth opportunities for the market in the coming years.

Croda International Plc. to Cover Majority Shares with Sterile Adjuvants

Croda International plc. had been operating in the global market for veterinary vaccine adjuvants ever since 1939. This acts as a major factor in helping this company dominate the market. Besides this, the vaccines developed by these companies are produced by an aseptic process which makes it one of a kind. This company is likely to continue dominating the market in the coming years as well. Apart from this, other vendors are engaging in strategic collaborations such as mergers and acquisitions, joint ventures, partnerships, contracts, and agreements, for attracting high veterinary vaccines adjuvants market revenue in the forecast duration.

Notable Industry Developments of Veterinary Vaccines Adjuvants Market include:

• August 2019 – Osprey Biotechnics Inc. was acquired by Phibro Animal Health Corporation for the development and production of microbial products.


• January 2019 – Croda International Plc., announced the acquisition of Brenntag Biosector for USD 75 million to strengthen their pharmaceutical offering.

List of Significant Veterinary Vaccine Adjuvants Market Manufacturers are:

• InvivoGen


• Croda International Plc


• OZ Biosciences


• Zoetis


• Avanti Polar Lipids, Inc. 


• Phibro Animal Health Corporation


• Merck & Co., Inc.


• SEPPIC


• Bioveta, A.S. 


• SPI Pharma


• Other Vendors

Further Report Findings

• North America held the dominant veterinary vaccine adjuvants market share with a revenue of USD 158.84 million in 2019 on account of the presence of well-established veterinary healthcare infrastructure in the developed nations and pet infrastructure facility.


• With respect to segmentation by type, the market is dominated by the alum and calcium salts segment with a 32.4 % share in 2019. This is because alum and calcium are the most commonly used adjuvants comprising of aluminum salts.

Global Veterinary Vaccine Adjuvants Market is Segmented into: